Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 164
interventional 136
Observational 26
Registry 2

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Biological 83
Drug 14
Biological|placebo 8
Drug|placebo 6
Device 5
Other 5
Biological|Other 3
Drug|Other 3
Procedure 2
Behavioral 1
Biological|Drug|Other|Procedure 1
Biological|Procedure 1
Combination Product 1
Diagnostic Test 1
Dietary Supplement 1
Drug|Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 26
NA 12
Germany 8
Austria 7
Austria|Germany 6
Philippines 6
Poland 6
Thailand 6
China 5
Korea, Republic of 5
Vietnam 5
United Kingdom 4
Australia 3
Austria|Germany|Poland 3
United States|Canada 3
Belgium 2
France 2
India 2
Philippines|Thailand 2
Russian Federation 2
Slovenia 2
Sri Lanka 2
Taiwan 2
United States|Australia 2
Austria|Czech Republic 1
Austria|Germany|Switzerland 1
Bangladesh 1
Czech Republic 1
Czech Republic|Germany 1
Czechia 1
Finland 1
Finland|Sweden 1
Nepal 1
Singapore 1
United States|Australia|Denmark|Germany|Sweden 1
United States|Australia|Germany 1
United States|Canada|Sweden|United Kingdom 1

Sites per Study

Site_count Study_Count
1 71
2 14
3 13
4 6
5 3
6 2
7 3
8 7
9 1
10 4
13 1
16 2
19 1
21 1
22 2
23 2
25 2
69 1

Phase

Phase Study_Count
Phase 3 40
Phase 4 33
Phase 2 27
N/A 21
Phase 1 10
Phase 1/Phase 2 2
Phase 2/Phase 3 2
Early Phase 1 1

Number of Arms

Number_of_Arms Count_of_Studies
1 27
2 42
3 21
4 13
5 3
6 3
NA 27

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 144 7.00000 10.00 22 22.0 200 23.0000 17.0000
1st Qu. 144 40.00000 22.00 32 50.0 200 262.0000 70.0000
Median 144 60.00000 29.00 42 100.0 200 389.0000 206.0000
Mean 144 96.89474 31.90 42 164.6 200 745.0256 575.1935
3rd Qu. 144 85.00000 44.25 52 200.0 200 740.5000 331.5000
Max. 144 600.00000 56.00 62 615.0 200 3973.0000 10000.0000

Trial Group Type

group_type Group_Count
Experimental 140
Active Comparator 80
NA 27
Placebo Comparator 18
Other 16
Sham Comparator 3
No Intervention 2

Intervention Model

intervention_model Study_Count
Parallel Assignment 81
Single Group Assignment 42
Crossover Assignment 5
NA 4
Factorial Assignment 2
Sequential Assignment 2

Primary Purpose

primary_purpose Study_Count
Prevention 90
Treatment 28
Basic Science 7
NA 6
Diagnostic 3
Health Services Research 1
Other 1

Observational Studies

Studies by Country

Country Study_Count
France 7
United States 6
NA 2
Austria 1
Canada 1
China 1
Denmark 1
Germany|Italy|United Kingdom 1
Korea, Republic of 1
Netherlands 1
Slovenia 1
Sweden 1
Switzerland 1
United Kingdom 1

Sites per Study

Site_count Study_Count
1 21
4 1
7 2
8 1
22 1

Enrollment Metrics

Measure Observational
Min 5.00
1st Qu 50.00
Median 100.00
Mean 1244.84
3rd Qu 690.00
Max 20000.00

Observation Model

observational_model Study_Count
Cohort 15
NA 4
Case-Only 3
Other 3
Case-Control 1

Time Perspective

time_perspective Study_Count
Prospective 11
Retrospective 9
NA 4
Cross-Sectional 1
Other 1

Registries

Studies by Country

Country Study_Count
Cambodia|Lao People’s Democratic Republic|Myanmar|Vietnam 1
Colombia 1

Sites per Study

Site_count Study_Count
7 1
8 1

Enrollment Metrics

Measure Registries
Min 570.0
1st Qu 627.5
Median 685.0
Mean 685.0
3rd Qu 742.5
Max 800.0

Registry Model

observational_model Study_Count
Case-Control 1
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 2

Follow-up

target_duration Study_Count
1 Year 1
4 Weeks 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03662750 TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort https://ClinicalTrials.gov/show/NCT03662750 Recruiting Imperial College London 2019-12-31
NCT03826056 Neurology Inpatient Clinical Education Trial https://ClinicalTrials.gov/show/NCT03826056 Active, not recruiting Dartmouth-Hitchcock Medical Center 2020-10-31
NCT03282370 Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam https://ClinicalTrials.gov/show/NCT03282370 Completed National Institute of Hygiene and Epidemiology, Vietnam 2018-02-06
NCT03204227 Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age https://ClinicalTrials.gov/show/NCT03204227 Completed National Institute of Hygiene and Epidemiology, Vietnam 2017-08-12
NCT03194815 IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2 https://ClinicalTrials.gov/show/NCT03194815 Recruiting University of Cambridge 2020-12-31
NCT03181945 Duration of Anti-convulsant Therapy for Acute Symptomatic Seizure in Acute Encephalitis Syndrome https://ClinicalTrials.gov/show/NCT03181945 Active, not recruiting Postgraduate Institute of Medical Education and Research 2018-09-30
NCT02910037 Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort https://ClinicalTrials.gov/show/NCT02910037 Completed University of California, San Francisco 2017-07-31
NCT02816554 Safety and Immunogenicity of JECEVAX in Young Children https://ClinicalTrials.gov/show/NCT02816554 Completed National Institute of Hygiene and Epidemiology, Vietnam 2015-09-30
NCT02654509 Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine https://ClinicalTrials.gov/show/NCT02654509 Completed U.S. Army Medical Research and Development Command 2016-02-16
NCT02643433 Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines https://ClinicalTrials.gov/show/NCT02643433 Completed Centers for Disease Control and Prevention, China 2016-06-30
NCT02602652 Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine https://ClinicalTrials.gov/show/NCT02602652 Completed Chulalongkorn University 2015-07-31
NCT02233868 Brain Inflammation and Function in Alcoholism https://ClinicalTrials.gov/show/NCT02233868 Recruiting National Institutes of Health Clinical Center (CC) 2024-12-31
NCT02538094 tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis https://ClinicalTrials.gov/show/NCT02538094 Completed Johns Hopkins University 2019-06-30
NCT02532569 Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj https://ClinicalTrials.gov/show/NCT02532569 Completed Boryung Pharmaceutical Co., Ltd 2016-10-31
NCT02526550 Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX https://ClinicalTrials.gov/show/NCT02526550 Completed Siriraj Hospital 2014-07-31
NCT02514746 Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose https://ClinicalTrials.gov/show/NCT02514746 Completed PATH 2016-12-15
NCT02511535 TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients https://ClinicalTrials.gov/show/NCT02511535 Completed Medical University of Vienna 2016-02-29
NCT02492165 Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects https://ClinicalTrials.gov/show/NCT02492165 Completed Sanofi 2016-03-31
NCT02479698 Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus https://ClinicalTrials.gov/show/NCT02479698 Recruiting M.D. Anderson Cancer Center 2020-07-31
NCT02463942 Tick-borne Encephalitis and Positive Borrelial Antibodies https://ClinicalTrials.gov/show/NCT02463942 Recruiting University Medical Centre Ljubljana 2020-09-30
NCT02367664 A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants https://ClinicalTrials.gov/show/NCT02367664 Completed Jiangsu Province Centers for Disease Control and Prevention 2016-06-30
NCT02308982 Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis https://ClinicalTrials.gov/show/NCT02308982 Active, not recruiting University of Oxford 2019-02-28
NCT02186626 Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age https://ClinicalTrials.gov/show/NCT02186626 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2016-07-31
NCT01296360 Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country https://ClinicalTrials.gov/show/NCT01296360 Completed Valneva Austria GmbH 2011-11-30
NCT02039440 6-year Antibody Check After Third Vaccination Against Japanese Encephalitis https://ClinicalTrials.gov/show/NCT02039440 Completed Medical University of Vienna 2014-06-30
NCT01991067 Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients https://ClinicalTrials.gov/show/NCT01991067 Completed Medical University of Vienna 2018-10-28
NCT01984983 Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers https://ClinicalTrials.gov/show/NCT01984983 Completed Ichor Medical Systems Incorporated 2014-06-30
NCT01981967 Post-licensure Safety Study of IMOJEV® in Thailand https://ClinicalTrials.gov/show/NCT01981967 Completed Sanofi 2015-04-30
NCT01943305 The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans https://ClinicalTrials.gov/show/NCT01943305 Completed Singapore General Hospital 2015-06-30
NCT01900444 Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea https://ClinicalTrials.gov/show/NCT01900444 Completed Sanofi 2014-03-11
NCT01856205 Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis https://ClinicalTrials.gov/show/NCT01856205 Completed University of Liverpool 2009-08-31
NCT01815073 Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine https://ClinicalTrials.gov/show/NCT01815073 Completed Changchun Keygen Biological Products Co., Ltd. 2013-07-31
NCT01662440 Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects https://ClinicalTrials.gov/show/NCT01662440 Completed Novartis 2012-12-31
NCT01656200 A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 https://ClinicalTrials.gov/show/NCT01656200 Completed Indian Institute of Science 2013-10-31
NCT01582698 TBE Seropersistence up to 10 Years After First Booster in Adults https://ClinicalTrials.gov/show/NCT01582698 Completed Baxter Healthcare Corporation 2015-06-30
NCT01567865 Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine https://ClinicalTrials.gov/show/NCT01567865 Completed PATH 2012-12-31
NCT01562444 Study to Evaluate Long Term Immunogenicity up to 10 Years After the First Booster Immunization With Tick Borne Encephalitis Vaccine in Adults Who Received 1 of 3 Different Primary Vaccination Schedules https://ClinicalTrials.gov/show/NCT01562444 Completed GlaxoSmithKline 2016-09-30
NCT01466387 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults https://ClinicalTrials.gov/show/NCT01466387 Completed Novartis 2012-04-30
NCT01408537 Immunogenicity and Safety of Inactivated Vero Cell Derived Japanese Encephalitis Vaccine in Thai Children https://ClinicalTrials.gov/show/NCT01408537 Completed Mahidol University 2012-10-31
NCT01398540 Cellular and Humoral Immunity in Elderly After Immunization With a Japanese Encephalitis Vaccine https://ClinicalTrials.gov/show/NCT01398540 Completed Medical University of Vienna 2012-10-31
NCT01396512 Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEVâ„¢) Compared to CD.JEVAXâ„¢ in Toddlers https://ClinicalTrials.gov/show/NCT01396512 Completed Sanofi 2013-03-31
NCT01386827 Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis https://ClinicalTrials.gov/show/NCT01386827 Completed Helsinki University Central Hospital 2011-04-30
NCT01361776 Humoral Response to Tick-borne Encephalitis Vaccine in Elderly https://ClinicalTrials.gov/show/NCT01361776 Completed Sormland County Council, Sweden 2013-12-31
NCT04361344 Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection https://ClinicalTrials.gov/show/NCT04361344 Recruiting Centre Hospitalier de PAU 2021-01-19
NCT04344626 Use of a Tonometer to Identify Epileptogenic Lesions During Pediatric Epilepsy Surgery https://ClinicalTrials.gov/show/NCT04344626 Recruiting University of California, Los Angeles 2023-03-31
NCT04343469 Effects of Morbid Obesity and Bariatric Surgery on Brain Inflammation, and Activation of Central Reward System https://ClinicalTrials.gov/show/NCT04343469 Recruiting Turku University Hospital 2022-09-30
NCT04325685 The Effect of Supraglottic and Oropharyngeal Decontamination on the Incidence of Ventilator-associated Pneumonia https://ClinicalTrials.gov/show/NCT04325685 Active, not recruiting Northern State Medical University 2021-12-31
NCT04323150 The Effect of Closed Suction System on the Incidence of Ventilator-associated Pneumonia. https://ClinicalTrials.gov/show/NCT04323150 Recruiting Northern State Medical University 2020-12-31
NCT04223037 Purified Inactivated Japanese Encephalitis Vaccine https://ClinicalTrials.gov/show/NCT04223037 Active, not recruiting Chinese Academy of Medical Sciences 2018-03-07
NCT04137159 An Exercise Intervention to Reduce Neuropathic Pain and Brain Inflammation After Spinal Cord Injury https://ClinicalTrials.gov/show/NCT04137159 Recruiting Spaulding Rehabilitation Hospital 2025-01-31
NCT04131595 Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects https://ClinicalTrials.gov/show/NCT04131595 Active, not recruiting Bavarian Nordic 2020-06-30
NCT04080921 Stem Cell Transplantation In-patient With Neurological Sequelae Due to Encephalitis or Meningitis https://ClinicalTrials.gov/show/NCT04080921 Completed Vinmec Research Institute of Stem Cell and Gene Technology 2019-06-30
NCT04017052 Application of a TBE-Vaccine in Obese Persons https://ClinicalTrials.gov/show/NCT04017052 Active, not recruiting Medical University of Vienna 2020-02-07
NCT04002219 Efficacy Evaluation of the Mushroom Beverage on Emotion Regulation https://ClinicalTrials.gov/show/NCT04002219 Recruiting National Science Council, Taiwan 2019-12-31
NCT03993262 Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis https://ClinicalTrials.gov/show/NCT03993262 Recruiting Jena University Hospital 2022-07-01
NCT03971058 Immune Responses After a Booster Immunisation With IXIARO® in Elderly Compared to Young Individuals. https://ClinicalTrials.gov/show/NCT03971058 Recruiting Medical University of Vienna 2020-12-31
NCT03956446 Tick-borne Encephalitis and Borrelial Antibodies in Serum https://ClinicalTrials.gov/show/NCT03956446 Recruiting University Medical Centre Ljubljana 2020-12-31
NCT03879603 VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults https://ClinicalTrials.gov/show/NCT03879603 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2020-02-26
NCT03835728 Efficacy of Ocrelizumab in Autoimmune Encephalitis https://ClinicalTrials.gov/show/NCT03835728 Recruiting University of Texas Southwestern Medical Center 2022-01-22
NCT03776994 Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine https://ClinicalTrials.gov/show/NCT03776994 Active, not recruiting SRI International 2020-07-31
NCT03542279 Immunotherapy in Autoimmune Encephalitis https://ClinicalTrials.gov/show/NCT03542279 Recruiting Xuanwu Hospital, Beijing 2021-12-31
NCT03435861 Effect of Neflamapimod on Brain Inflammation in Alzheimer’s Disease Patients https://ClinicalTrials.gov/show/NCT03435861 Recruiting University Hospital, Toulouse 2020-01-30
NCT01246479 Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study https://ClinicalTrials.gov/show/NCT01246479 Completed Valneva Austria GmbH 2012-10-31
NCT01190228 Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV https://ClinicalTrials.gov/show/NCT01190228 Completed Sanofi 2010-10-29
NCT01188343 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers https://ClinicalTrials.gov/show/NCT01188343 Completed Sanofi 2012-07-31
NCT01159561 Western Equine Encephalitis Vaccine, Inactivated https://ClinicalTrials.gov/show/NCT01159561 Completed U.S. Army Medical Research and Development Command 2011-08-31
NCT01158599 This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population https://ClinicalTrials.gov/show/NCT01158599 Completed Valneva Austria GmbH 2011-06-30
NCT01150942 Clinical Trial to Assess the Immunogenicity and Safety of the Vero Cell-derived JE Vaccine in Korea https://ClinicalTrials.gov/show/NCT01150942 Completed Boryung Pharmaceutical Co., Ltd 2012-09-30
NCT01106482 An Extension Study to Determine the Persistence of Tick-borne Encephalitis (TBE)-Specific Antibody Responses Among Children and Adolescents Previously Immunized Against TBE https://ClinicalTrials.gov/show/NCT01106482 Completed Novartis 2011-05-31
NCT01092507 A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers https://ClinicalTrials.gov/show/NCT01092507 Completed Sanofi 2011-09-30
NCT01041573 Safety and Immunogenicity of the Japanese Encephalitis Vaccine IC51 (IXIARO®) in a Pediatric Population https://ClinicalTrials.gov/show/NCT01041573 Completed Valneva Austria GmbH 2011-02-28
NCT01001988 Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers https://ClinicalTrials.gov/show/NCT01001988 Completed Sanofi 2013-10-16
NCT00982137 Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) https://ClinicalTrials.gov/show/NCT00982137 Completed Sanofi 2005-04-30
NCT00981630 Study of Live Attenuated ChimeriVaxâ„¢-Japanese Encephalitis Vaccine https://ClinicalTrials.gov/show/NCT00981630 Completed Sanofi 2006-02-28
NCT00981175 A Study of ChimeriVaxâ„¢-JE Live Attenuated Vaccine in Healthy Adults https://ClinicalTrials.gov/show/NCT00981175 Completed Sanofi 2004-06-30
NCT00894686 Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401) https://ClinicalTrials.gov/show/NCT00894686 Completed Pfizer 2017-05-10
NCT00840801 Immunogenicity, Safety and Interchangeability of Two Tbe Vaccines Administered According to a Conventional Schedule in Children https://ClinicalTrials.gov/show/NCT00840801 Completed Pfizer 2009-05-31
NCT02880865 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine https://ClinicalTrials.gov/show/NCT02880865 Completed PATH 2017-05-19
NCT01865578 Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis https://ClinicalTrials.gov/show/NCT01865578 Completed Charite University, Berlin, Germany 2015-05-31
NCT01710189 Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac https://ClinicalTrials.gov/show/NCT01710189 Completed University of Surrey 2014-10-31
NCT00804219 Humoral and Cellular Immunity of Low and High-responders After Tick-borne Encephalitis Vaccination https://ClinicalTrials.gov/show/NCT00804219 Completed Medical University of Vienna 2010-11-30
NCT01047839 Immunogenicity and Safety of the Japanese Encephalitis Vaccine IC51 (IXIARO®, JESPECT®) in a Pediatric Population in Non-endemic Countries https://ClinicalTrials.gov/show/NCT01047839 Completed Valneva Austria GmbH 2013-08-31
NCT02466750 Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine https://ClinicalTrials.gov/show/NCT02466750 Recruiting U.S. Army Medical Research and Development Command 2020-06-30
NCT04175522 Safety and Efficacy of IGIV 10% in Patients With Autoimmune Encephalitis: https://ClinicalTrials.gov/show/NCT04175522 Completed Green Cross Corporation 2020-06-11
NCT00776230 Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling https://ClinicalTrials.gov/show/NCT00776230 Completed Valneva Austria GmbH 2010-06-30
NCT00735644 Study of ChimeriVaxâ„¢-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines https://ClinicalTrials.gov/show/NCT00735644 Completed Sanofi 2009-05-31
NCT00716066 Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases https://ClinicalTrials.gov/show/NCT00716066 Recruiting Fred Hutchinson Cancer Research Center 2026-03-31
NCT00694460 Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers https://ClinicalTrials.gov/show/NCT00694460 Completed Novartis 2004-08-31
NCT00621764 Immunogenicity and Safety of ChimeriVaxâ„¢ Japanese Encephalitis Vaccine in Thai Toddlers and Children https://ClinicalTrials.gov/show/NCT00621764 Completed Sanofi 2009-12-31
NCT00605085 Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 https://ClinicalTrials.gov/show/NCT00605085 Completed Valneva Austria GmbH NA
NCT00604708 Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 https://ClinicalTrials.gov/show/NCT00604708 Completed Valneva Austria GmbH 2006-09-30
NCT00596271 Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440 https://ClinicalTrials.gov/show/NCT00596271 Completed Valneva Austria GmbH 2006-07-31
NCT00595790 Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51 https://ClinicalTrials.gov/show/NCT00595790 Completed Valneva Austria GmbH 2006-02-28
NCT00595465 Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51 https://ClinicalTrials.gov/show/NCT00595465 Completed Valneva Austria GmbH 2008-02-29
NCT00595309 Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 https://ClinicalTrials.gov/show/NCT00595309 Completed Valneva Austria GmbH 2009-10-31
NCT00595270 Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 https://ClinicalTrials.gov/show/NCT00595270 Completed Valneva Austria GmbH 2007-09-30
NCT00594958 Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 https://ClinicalTrials.gov/show/NCT00594958 Completed Valneva Austria GmbH 2007-04-30
NCT00584805 Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine https://ClinicalTrials.gov/show/NCT00584805 Completed U.S. Army Medical Research and Development Command 2016-06-27
NCT00503529 TBE Antibody Persistence and Booster Vaccination Study in Adults (Follow-up to Study 223) https://ClinicalTrials.gov/show/NCT00503529 Completed Pfizer 2010-07-31
NCT00463684 Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age https://ClinicalTrials.gov/show/NCT00463684 Completed PATH 2007-11-07
NCT00463476 Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine https://ClinicalTrials.gov/show/NCT00463476 Completed PATH 2007-11-01
NCT00460486 Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule https://ClinicalTrials.gov/show/NCT00460486 Completed Pfizer 2007-11-30
NCT00452621 Evaluation of Long-Term Immunogenicity in Children and Adolescents Boosted With a New Pediatric TBE Vaccine After Five Years https://ClinicalTrials.gov/show/NCT00452621 Completed Novartis NA
NCT00441259 Safety and Efficacy Study of ChimeriVaxâ„¢-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age https://ClinicalTrials.gov/show/NCT00441259 Completed Sanofi 2011-02-28
NCT00412516 Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine https://ClinicalTrials.gov/show/NCT00412516 Completed PATH 2010-03-31
NCT00387634 Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis’ TBE Vaccine for Adults in Adolescents and Adults https://ClinicalTrials.gov/show/NCT00387634 Completed Novartis 2011-10-31
NCT00381433 Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid https://ClinicalTrials.gov/show/NCT00381433 Completed Sarepta Therapeutics, Inc. 2006-10-31
NCT00367081 Treatment of Cerebral Toxoplasmosis in HIV/AIDS https://ClinicalTrials.gov/show/NCT00367081 Completed Rajavithi Hospital NA
NCT00319592 A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX https://ClinicalTrials.gov/show/NCT00319592 Completed Sanofi 2006-09-30
NCT00314145 A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxâ„¢-JE and JE-VAX https://ClinicalTrials.gov/show/NCT00314145 Completed Sanofi 2006-06-30
NCT00314132 Safety Study of ChimeriVaxâ„¢-JE Vaccine to Prevent Japanese Encephalitis. https://ClinicalTrials.gov/show/NCT00314132 Completed Sanofi 2006-11-30
NCT00311493 Evaluation of Long-Term Immunogenicity in Subjects Boosted With a TBE Vaccine for Adults https://ClinicalTrials.gov/show/NCT00311493 Completed Novartis NA
NCT00311441 Study of the Safety, Tolerability and Immune Response of TBE Vaccines Administered to Healthy Children https://ClinicalTrials.gov/show/NCT00311441 Completed Novartis NA
NCT00259805 A Pilot Study of the Use of Rituximab in the Treatment of Chronic Focal Encephalitis https://ClinicalTrials.gov/show/NCT00259805 Completed California Pacific Medical Center Research Institute 2008-12-31
NCT00249769 Determining Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine https://ClinicalTrials.gov/show/NCT00249769 Completed PATH 2006-05-30
NCT00163540 Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225) https://ClinicalTrials.gov/show/NCT00163540 Completed Pfizer NA
NCT00161967 TBE Antibody Persistence and Booster Vaccination Study in Children and Adolescents (Follow-up to Study 209) https://ClinicalTrials.gov/show/NCT00161967 Completed Pfizer 2008-07-31
NCT00161954 Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years https://ClinicalTrials.gov/show/NCT00161954 Completed Pfizer NA
NCT00161889 FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years https://ClinicalTrials.gov/show/NCT00161889 Completed Pfizer NA
NCT00161876 FSME IMMUN NEW Follow-up to Study 208 in Volunteers Aged 16 to 66 Years https://ClinicalTrials.gov/show/NCT00161876 Completed Pfizer NA
NCT00161863 Safety Study of FSME-IMMUN NEW in Healthy Children and Adolescents Aged 1 to 15 Years https://ClinicalTrials.gov/show/NCT00161863 Completed Pfizer NA
NCT00161850 FSME IMMUN NEW Follow-up to Study 199 in Children Aged 1 to 6 Years https://ClinicalTrials.gov/show/NCT00161850 Completed Pfizer NA
NCT00161824 Safety Study in Volunteers From 16 to 65 Years of Age: FSME IMMUN NEW vs. ENCEPUR https://ClinicalTrials.gov/show/NCT00161824 Completed Pfizer NA
NCT00161798 Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years. https://ClinicalTrials.gov/show/NCT00161798 Completed Pfizer NA
NCT00161785 Investigation of the Seropersistence of TBE Antibodies and the Booster Response to FSME-IMMUN 0.5 ml in Adults Aged 18 - 67 Years https://ClinicalTrials.gov/show/NCT00161785 Completed Pfizer NA
NCT00161772 Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years. https://ClinicalTrials.gov/show/NCT00161772 Completed Pfizer NA
NCT00161746 Safety and Immunogenicity Study of 3 Vaccinations With TICOVAC in 2 Dosages in Healthy Children Aged Between 6 Months and 3 Years https://ClinicalTrials.gov/show/NCT00161746 Completed Pfizer NA
NCT00118924 Safety of and Immune Response to a Tick-Borne Encephalitis Vaccine (LGT(TP21)/DEN4) in Healthy Adults https://ClinicalTrials.gov/show/NCT00118924 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2007-07-31
NCT00094718 Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3’delta30) in Healthy Adults https://ClinicalTrials.gov/show/NCT00094718 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2005-04-30
NCT00068055 IVIG - West Nile Encephalitis: Safety and Efficacy https://ClinicalTrials.gov/show/NCT00068055 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2006-12-31
NCT00031486 Long Term Treatment of Herpes Simplex Encephalitis (HSE) With Valacyclovir https://ClinicalTrials.gov/show/NCT00031486 Completed National Institute of Allergy and Infectious Diseases (NIAID) 2010-06-30
NCT00002064 Toxoplasmic Encephalitis in Patients With AIDS. Treatment and Prevention of Relapse https://ClinicalTrials.gov/show/NCT00002064 Completed NIH AIDS Clinical Trials Information Service NA
NCT00001994 A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine https://ClinicalTrials.gov/show/NCT00001994 Completed NIH AIDS Clinical Trials Information Service NA
NCT00000794 Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis https://ClinicalTrials.gov/show/NCT00000794 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000674 A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS https://ClinicalTrials.gov/show/NCT00000674 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00000666 A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma Gondii Infection https://ClinicalTrials.gov/show/NCT00000666 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04460599 Neurological Features of SARS COV 2 Infection https://ClinicalTrials.gov/show/NCT04460599 Recruiting Centre d’Investigation Clinique et Technologique 805 2020-07-30
NCT03418441 Central Nervous System Infections in Denmark https://ClinicalTrials.gov/show/NCT03418441 Recruiting Aalborg University Hospital 2025-01-01
NCT03242395 PRIME: Cognitive Outcome Following Major Burns https://ClinicalTrials.gov/show/NCT03242395 Completed Chelsea and Westminster NHS Foundation Trust 2017-02-28
NCT03027232 Control of Leukocyte Function https://ClinicalTrials.gov/show/NCT03027232 Completed Beth Israel Deaconess Medical Center 2017-12-15
NCT02983318 Molecular Imaging of Brain Inflammation in Depressive Disorders https://ClinicalTrials.gov/show/NCT02983318 Completed Lawson Health Research Institute 2019-03-20
NCT02979951 Fosfomycin i.v. for Treatment of Severely Infected Patients https://ClinicalTrials.gov/show/NCT02979951 Recruiting Infectopharm Arzneimittel GmbH 2020-06-30
NCT02933710 Postmarketing Surveillance Study for IMOJEV® in Republic of Korea https://ClinicalTrials.gov/show/NCT02933710 Completed Sanofi 2018-10-18
NCT02906631 Epidemiology and Prognosis of Encephalitis in Intensive Care https://ClinicalTrials.gov/show/NCT02906631 Recruiting Assistance Publique - Hôpitaux de Paris 2021-07-31
NCT02905136 Mechanisms of Auto-immune Encephalitis https://ClinicalTrials.gov/show/NCT02905136 Active, not recruiting Hospices Civils de Lyon 2018-09-30
NCT02802475 Antibodies Causing Epilepsy Syndromes: The ACES Study. https://ClinicalTrials.gov/show/NCT02802475 Recruiting Erasmus Medical Center 2019-01-31
NCT04339205 Diffusion Imaging in Acute Auto-immune Encephalitis https://ClinicalTrials.gov/show/NCT04339205 Recruiting Hospices Civils de Lyon 2020-03-01
NCT01851356 Brain Inflammation in Major Depressive Disorder Background https://ClinicalTrials.gov/show/NCT01851356 Completed National Institutes of Health Clinical Center (CC) 2017-07-27
NCT01694524 Nervous System Infections Among Patients With Febrile Seizure https://ClinicalTrials.gov/show/NCT01694524 Completed Hôpital Armand Trousseau 2014-03-31
NCT01335412 Safety Surveillance After Immunization With IXIARO https://ClinicalTrials.gov/show/NCT01335412 Completed Valneva Austria GmbH 2013-06-30
NCT04339127 Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis https://ClinicalTrials.gov/show/NCT04339127 Recruiting Hospices Civils de Lyon 2020-06-01
NCT03958058 Tick-borne Encephalitis and Possible Borrelial Serology https://ClinicalTrials.gov/show/NCT03958058 Completed University Medical Centre Ljubljana 2013-12-31
NCT03856528 Infections of the Central Nervous System https://ClinicalTrials.gov/show/NCT03856528 Completed University Hospital, Basel, Switzerland 2019-09-01
NCT03710278 The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat) https://ClinicalTrials.gov/show/NCT03710278 Completed Spartanburg Regional Healthcare System 2019-01-23
NCT03530462 To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI https://ClinicalTrials.gov/show/NCT03530462 Completed First Affiliated Hospital of Zhejiang University 2018-02-28
NCT03872284 Neuro-ophthalmology and Autoimmune Encephalitis (NODE) https://ClinicalTrials.gov/show/NCT03872284 Recruiting Hospices Civils de Lyon 2027-01-24
NCT02856451 Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab https://ClinicalTrials.gov/show/NCT02856451 Active, not recruiting Bristol-Myers Squibb 2021-12-31
NCT03932448 Fever After Tick Bite Study https://ClinicalTrials.gov/show/NCT03932448 Recruiting Göteborg University 2022-12-20
NCT00596102 Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51 https://ClinicalTrials.gov/show/NCT00596102 Completed Valneva Austria GmbH 2011-03-31
NCT00163618 Study to Investigate the Seropersistence of TBE Virus Antibodies Approx. 3 Years After a Booster Vaccination With FSME-IMMUN 0.25 mL JUNIOR in Children https://ClinicalTrials.gov/show/NCT00163618 Completed Pfizer NA
NCT00069303 Natural History of West Nile Virus Infection https://ClinicalTrials.gov/show/NCT00069303 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001648 Structure of the Herpes Simplex Virus Receptor https://ClinicalTrials.gov/show/NCT00001648 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03206541 Neurologic Manifestations of the Arbovirus Infection in Colombia https://ClinicalTrials.gov/show/NCT03206541 Completed Johns Hopkins University 2019-12-31
NCT04089436 SouthEast Asia Encephalitis Project https://ClinicalTrials.gov/show/NCT04089436 Active, not recruiting Institut Pasteur 2019-09-30